{"id":"agn-210669-ophthalmic-solution-0-05","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased intraocular pressure"}]},"_chembl":{"chemblId":"CHEMBL4303670","moleculeType":"Small molecule","molecularWeight":"424.57"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Corticosteroids like AGN-210669 work by inhibiting the production of inflammatory mediators, thereby reducing swelling and pain in the eye. This is achieved through the suppression of phospholipase A2, an enzyme involved in the production of prostaglandins and leukotrienes, which are key players in the inflammatory response.","oneSentence":"AGN-210669 ophthalmic solution is a corticosteroid used to reduce inflammation in the eye.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:20:17.624Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of non-infectious uveitis affecting the posterior segment of the eye"}]},"trialDetails":[{"nctId":"NCT01291108","phase":"PHASE2","title":"Safety and Efficacy of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-04","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":125},{"nctId":"NCT00809848","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-02","conditions":"Ocular Hypertension, Glaucoma","enrollment":172},{"nctId":"NCT01001195","phase":"PHASE2","title":"Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-11","conditions":"Glaucoma, Open-Angle, Ocular Hypertension","enrollment":165}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AGN-210669 ophthalmic solution, 0.05%","genericName":"AGN-210669 ophthalmic solution, 0.05%","companyName":"Allergan","companyId":"allergan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AGN-210669 ophthalmic solution is a small molecule used to treat conditions such as open-angle glaucoma and ocular hypertension. It is compared to bimatoprost ophthalmic solution in clinical trials for its safety and efficacy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}